A Study to Evaluate Safety and Efficacy of PBK_M2502

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

November 30, 2026

Conditions
Intestinal DiseaseColonic DiseasesGastrointestinal DiseaseDigestive System Disease
Interventions
DRUG

PBK_M2502 1-Day

Subjects who are randomized into group test 2 will receive bowel preparation on the same-day.

DRUG

PBK_M2502 2-Day

Subjects who are randomized into group test 1 will receive bowel preparation from evening to next morning.

Trial Locations (1)

Unknown

Kyung Hee University Hospital at Gangdong, Seoul

Sponsors
All Listed Sponsors
lead

Pharmbio Korea Co., Ltd.

INDUSTRY

NCT07114406 - A Study to Evaluate Safety and Efficacy of PBK_M2502 | Biotech Hunter | Biotech Hunter